Neurogenic Compounds for Treating Diabetic Complications

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,000,000.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK069733-01
Award Id:
71577
Agency Tracking Number:
DK069733
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
BIOMEDICAL RESEARCH MODELS, INC., 67 MILLBROOK, ST, STE 422, WORCESTER, MA, 01606
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
REBECCA TIRABASSI
(508) 459-7544
RTIRABASSI@BIOMERE.COM
Business Contact:
(508) 459-7544
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Neuronal dysfunction is the leading complication associated with diabetes. Diabetic patients experience both cognitive impairment and a collection of syndromes termed "diabetic neuropathies". Although many of the pathways involved in initiating hyperglycemic-induced neuronal degeneration have been identified, promising therapies directed at preventing and alleviating symptoms are still lacking. With funding from the DOD, we have identified several small molecules which both enhance neurogenesis and protect neurons from apoptosis. We propose to develop these molecules as new compounds to treat neuronal dysfunction in type 1 diabetes. In Phase 1, we will re-screen our leading compounds to determine which compounds protect neurons in diabetes-specific in vitro assays. We will then determine whether prophylactic administration of these compounds has an effect on cognitive impairment and early symptoms of diabetic polyneuropathy in a rat model of spontaneous type 1 diabetes. In addition, we will perform dose response, acute toxicity and pharmacokinetic studies. Based on these results, we will choose one lead compound for further studies. In Phase 2 we will determine whether the lead compound also acts therapeutically when given within a certain time period post onset of diabetes. We will expand toxicity studies and we will test the molecule in a variety of diabetic animal models. The end result of these studies will be the identification of one lead compound to be developed as an IND/therapy in the treatment of diabetic polyneuropathy and/or diabetic encephalopathy.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government